Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma

Annals of Hematology

Volumn 79, Issue 4, 2000, Pages 167-174

  Feuring Buske, M ^a,b   Buske, C ^a   Unterhalt, M ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Antibody therapy; CD20; Chimeric antibody; Immunotoxin; Malignant lymphoma; Radioimmunoconjugate

Indexed keywords

ANTIBODY CONJUGATE; CD20 ANTIGEN; CHIMERIC ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOTOXIN; INTERLEUKIN 2; IODINE 131; LYMPHOCYTE ANTIGEN; MITOXANTRONE; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; RADIOISOTOPE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB;

APHASIA; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL; CYTOPENIA; DRUG EFFICACY; DRUG TOXICITY; FEVER; GENETIC ENGINEERING; HUMAN; LIVER TOXICITY; LUNG EDEMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; THROMBOCYTOPENIA;

EID: 0034100281     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050575     Document Type: Review

References (80)

1. Anderson-Berg WT, Squire RA, Strand M (1987) Specific radioimmunotherapy using 90-Y labeled antibody in erythroleukemic mice. Cancer Res 47:1905-1912
2. Bakina E, Wu Z, Rosenblum M, Farquhar D (1997) Intensely cytotoxic anthracycline prodrugs: glucuronides. J Med Chem 40:4013-4018
3. Bastion Y, Brice P, Haioun C, et al (1995) Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262
4. Bernstein ID, Tam MR, Nowinski RC (1980) Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science 207:68-71
5. Bierman PJ, Vose JM, Anderson JR, et al (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450
6. Brinkmann U, Pastan I (1995) Recombinant immunotoxins: from basic research to cancer therapy. Methods 8:143-156
7. Brown SL, Miller RA, Homing SJ (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651-661
8. Cabanillas F, Grillo-Lopez AJ, McLaughlin P (1996) AntiCD20 antibody (MAB), IDEC-C2B8:clearance of bcl-2 t(14;18) positive cells from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular lymphoma (LG/F NHL). Blood 88 [Suppl 1]:91a
9. Coiffier B, Haioun C, Ketterer N (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients wih relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-1932
10. Corcoran MC, Eary J, Bernstein I, Press OW (1997) Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Ann Oncol 8 [Suppl 1]: S133-S138
11. Czuczman MS, Straus DJ, Divgi CR (1993) Phase I doseescalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11:2021-2029
12. ™ (Rituximab, IDEC-C2B8) have significant efficacy, do not cause HAMA and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood 90 [Suppl 1]: 509a
13. Davis T, Maloney D, White CA (1998) Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with Rituximab and alpha interferon: interim analysis. Proc Am Soc Clin Oncol 17: 11a
14. Demanet C, Brissinck J, Leo O, Moser M, Thielemans K (1994) Role of T-cell subsets in the bispecific antibody (antiidiotype X anti-CD3) treatment of the BCL-1 lymphoma. Cancer Res 54:2973-2978
15. Eiklid K, Olsnes S, Pihl A (1980) Entry of lethal doses of abrin, ricin and modeccin in the cytosol of HeLa cells. Exp Cell Res 126:321-326
16. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183-3191
17. Frankel AE, FitzGerald D, Siegall C, Press OW (1996) Advances in immunotoxin biology and therapy: a summary of the fourth international symposium on immunotoxins. Cancer Res 56:926-932
18. Freedman AS, Gribben JG, Neuberg D, et al (1998) Highdose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Leuk Lymphoma 28:219-230
19. Gisselbrecht C, Lepage E, Morel P, et al (1996) Short and intensified treatment with autologous stem cell transplantation versus ACVB regimen in poor prognosis aggressive lymphoma. Prognostic factors of induction failure. Ann Oncol 7:18 [Suppl 3]
20. Grossbard ML, Nadler LM (1993) Monoclonal antibody therapy for indolent lymphomas: Sem Oncol 5 [Suppl 5]: 118-135
21. Grossbard ML, Lambert JM, Goldmacher VS (1993) AntiB4-blocked ricin: a phase I trail of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726-737
22. Grossbard ML, Niedzwiecki D, Nadler LM (1998) Anti-B4-blocked ricin (anti-B4-bR) adjuvant therapy post-autologous bone marrow transplant (ABMT) (CALGB 9254): a phase III intergroup study. Proc Am Soc Clin Oncol 17:3a
23. Haagen I-A, Geerars AJ, de Lau WB (1994) Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 84:556-563
24. Haas R, Moos M, Karcher A, et al (1994) Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 2:1685-1692
25. Haioun C, Lepage E, Gisselbrecht C, et al (1994) Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients. J Clin Oncol 12:2543-2551
26. Hiddemann W (1995) Non-Hodgkin's lymphomas-current status of therapy and future perspectives. Eur J Cancer 31:2141-2145
27. Hiddemann W, Unterhalt M, Herrmann R (1998) Mantle cell lymphomas have more widespread disease and a slower response to chemotherapy as compared to follicle center lymphomas. Result of a prospective comparative analysis of the German Low Grade Lymphoma Study Group. J Clin Oncol 16:1922-1930
28. Hsu FJ, Caspar CB, Czerwinsky D (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89:3129-3135
29. Jones PT, Dear PH, Foots J, Neuberber MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525
30. Jurcic JG, Caron PC, Scheinberg DA (1995) Monoclonal antibody therapy of leukemia and lymphoma. Adv Pharm 33:287-314
31. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R (1986) Importance of antibody isotype in monoclonal antiidiotye therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 136:1123-1130
32. Kaminski MS, Fig LM, Zasadny KR (1992) Imaging, dosimetry, and radioimmunotherapy with iodine-131-labeled antiCD37 antibody in B-cell lymphoma. J Clin Oncol 2:1696-1711
33. Kaminski MS, Zasadny KR, Francis IR (1993) Radiommuno-therapy of B-cell lymphoma with [131I] anti-B I (anti-CD20) antibody. N Engl J Med 329:459-465
34. Kaminski MS, Zasadny KR, Francis IR (1996) Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981
35. Kaminski MS, Gribbin T, Estes J (1998). I-131-anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proc Am Soc Clin Oncol 17:2a
36. Kobayashi H, Sakahara H, Hosono M (1994) Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a 'chase' without decreased accumulation in the target tumor. J Nucl Med 35:1677-1684
37. Kollmannsberger C, Hartmann JT, Kanz L, Bokerneyer C (1998) Risk of secondary myeloid leukemia and myelodys-plastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 124:207-214
38. Kotz D (1998) Alpha particle therapy poised to become new line of cancer treatment. J Nucl Med 39:17N-19N
39. 486IL-2 (OntakTM) for the treatment of mycoses fungoides (MF). Blood 90 [Suppl 1]: 586a
40. 486IL-2) in hematological malignancies expressing the IL-2 receptor. Blood 79:2547-2554
41. Link BK, Grossbard ML, Fisher RI (1998) Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade NHL. Proc Am Soc Clin Oncol 17:3a
42. LoBuglio AF, Wheeler RH, Trang J (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 6:4220-4224
43. Longo D (1993) What's the deal with follicular lymphoma? J Clin Oncol 11:202-208
44. Maloney DG, Brown S, Czerwinski DK (1992). Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect or prevent the emergence of idiotype-negative variant cells. Blood 80:1502-1510
45. Maloney DG, Liles TM, Czerwinski DK (1994). Phase I clinical trial using escalating single-dose infusion of chimeric antiCD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466
46. Maloney DG, Smith B, Appelbaum FR (1996) The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 83:637a
47. Maloney DG, Grillo-Lopez AJ, Bodkin D (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274
48. Maloney DG, Grillo-Lopez AJ, White CA (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195
49. Marks C, Marks JD (1996) Phage libraries - a new route to clinically useful antibodies. N Engl J Med 335:730-733
50. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
51. Morrison SL (1986) Transfectomas provide novel chimeric antibodies. Science 229:379-393
52. Nichols J, Foss F, Kuzel TM (1997) Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 33 [Suppl 1]: S34-S36
53. Order SE, Klein JL, Leichner PK, Frincke J, Lollo C, Carlo DJ (1986) 90Yttrium antiferritin - a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 12:277-281
54. Order SE, Sleeper AM, Stillwagon GB, Klein JL, Leichner PK (1990) Radiolabeled antibodies: results and potential in cancer therapy. Cancer Res 50:1011s-1013s
55. Paganelli G, Magnani P, Zito F (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 51:5960-5966
56. Press OW, Appelbaum F, Ledbetter JA (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591
57. Press OW, Eary JF, Badger CC (1989) Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027-1038
58. Press OW, Eary JF, Appelbaum FR (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1924
59. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340
60. Reff ME, Carrier K, Chambers KS (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
61. Rizzieri DA, Chao NJ (1997) Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support. Curr Opin Oncol 9:420-427
62. Rogers J, Jackson J, Rosenberg J (1996) Clearance of bcl-2 (t 14; 18) from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular (IWF: A-D) lymphoma (NHL) following single-agent therapy with the chimeric anti-CD20 antibody (MAB) IDEC-C2B8. Ann Oncol 7:108a
63. Rohatiner AZ, Freedman A, Nadler L, et al (1994) Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 5:143-146 [Suppl 2]
64. Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J (1991) Anti-My 9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 77:2404-2412
65. 486IL-2, an IL-2-diphtheria fusion toxin. Blood 78 [Suppl]: 175a
66. Senter PD, Saulnier MG, Schreiber GJ (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A 85:4842-4846
67. Shouten HC, Colombat P, Verdonck LF, et al (1994) Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. Ann Oncol 5:147-149 [Suppl 2]
68. Skerra A (1993) Bacterial expression of immunoglobulin fragments. Curr Opin Immunol 5:256-262
69. Smalley RV, Andersen JW, Hawkins MJ (1992) Interferon alpha combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341
70. Solal-Celigny P, Lepage E, Brousse N (1993) Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl I Med 329:1608-1614
71. Stone MJ, Sausville EA, Fay JW (1996) A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88:1188-1197
72. Swisher EM, Shawler DL, Collins HA (1991) Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 77:1977-1982
73. Travis LB, Curtis R, Stovall M, et al (1994) Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457
74. Unterhalt M, Hermann R, Koch P (1995) Significant prolongation of disease-free survival in advanced low-grade non-Hodgkin's lymphoma. Blood 86:439A [Suppl 1]
75. Unterhalt M, Herrmann R, Tiemann M (1996) Prednimustine, mitoxantrone (PMM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced lowgrade non-Hodgkin lymphoma. Leukemia 10:836-843
76. Unterhalt M, Herrmann R, Koch P (1997) Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG). Blood 90 [Suppl 1]: 1743a
77. Van Endert PM, Heilig B, Harnmerling G, Moldenhauer G (1992) Monoclonal antibodies to idiotype inhibit in vitro growth of human B-cell lymphomas. Blood 79:129-137
78. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JWI (1987) Redesigning nature's poisons to create antitumor reagents. Science 238:1098-1104
79. Vitetta ES, Stone M, Amlot P (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052-4058
80. Weiner GJ, Hillstrom JR (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147:4035-4044